Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Saxagliptin – Treatment for Type 2 Diabetes

Drug (Brand/Generic)

Onglyza™/saxagliptin

Company/Licensee

AstraZeneca & BMS

Therapy Class

DPP-IV inhibitor

Product Description

Inhibits action of DPP-IV so delaying degradation of GLP-1

Current Indication

Type 2 diabetes

Market Sector

Diabetes

Development Status

Phase IIIb and IV in progress

Approvals

Approved in the US, Europe and Canada
Expand
Close
Close
Close

Go Top